Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Braftovi

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

- PMLiVE

Pfizer enters $210m+ nanomedicines deal with Bind

Will use Accurin technology to develop highly selective medicines

- PMLiVE

Roche launches test for thyroid cancer

Elecsys Calcitonin to support diagnosis of relapse following surgery

- PMLiVE

Charity says patients worried about Cancer Drugs Fund’s future

Beating Bowel Cancer demands clarity from DH about future for access to cancer medicines in England

- PMLiVE

Pfizer partners with hospital to research medicines for children

Children’s Hospital of Philadelphia joins CTI translational research network

- PMLiVE

Pfizer’s Bosulif gets conditional green light for CML in Europe

Follows US approval last year

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

inVentiv invests in virtual trials

Acquires equity stake in US-based Mytrus

- PMLiVE

Former Pfizer R&D head LaMattina to advise Ziarco

He previously spent 30 years at US pharma firm

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links